Free tool
FAERS Monitor: Xeljanz Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208246 or its brand name (Xeljanz Xr, Tofacitinib Citrate). Reports on generic versions are filed under their own applications.
Reports
184,023
Serious
88,585
48% of reports
Hospitalization
25,552
Death reported
9,502
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective43,969
- pain26,135
- arthralgia20,062
- condition aggravated19,789
- rheumatoid arthritis19,208
- fatigue16,945
- off label use15,236
- joint swelling14,808
- headache13,701
- rash12,289
- drug intolerance12,020
- malaise10,773
- pain in extremity10,467
- abdominal discomfort10,454
- nausea10,213
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 30 |
| 2013 | 1,743 |
| 2014 | 2,735 |
| 2015 | 4,604 |
| 2016 | 9,473 |
| 2017 | 15,399 |
| 2018 | 20,836 |
| 2019 | 22,021 |
| 2020 | 27,376 |
| 2021 | 19,223 |
| 2022 | 24,837 |
| 2023 | 14,046 |
| 2024 | 11,500 |
| 2025 | 8,234 |
| 2026 | 1,962 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,870,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 19,208 | 23.1 | 22.7 | 338,765 |
| drug intoleranceSignal | 12,020 | 16.1 | 15.8 | 149,724 |
| joint swellingSignal | 14,808 | 15.8 | 15.6 | 181,672 |
| condition aggravatedSignal | 19,789 | 7.9 | 7.8 | 112,895 |
| abdominal discomfortSignal | 10,454 | 7.5 | 7.4 | 55,946 |
| arthralgiaSignal | 20,062 | 5.7 | 5.7 | 76,310 |
| painSignal | 26,135 | 5.0 | 5.0 | 83,331 |
| pain in extremitySignal | 10,467 | 4.2 | 4.1 | 24,698 |
| drug ineffectiveSignal | 43,969 | 3.9 | 3.9 | 98,209 |
| rashSignal | 12,289 | 3.3 | 3.2 | 19,400 |
| malaiseSignal | 10,773 | 2.9 | 2.8 | 12,914 |
| headacheSignal | 13,701 | 2.5 | 2.5 | 12,793 |
| fatigueSignal | 16,945 | 2.5 | 2.5 | 15,790 |
| off label useSignal | 15,236 | 2.0 | 2.0 | 7,883 |
| nausea | 10,213 | 1.5 | 1.5 | 1,636 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.